Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "AAAAI 2026"

Argo Biopharma to Present Phase II Interim Data on BW-20805 for HAE at AAAAI 2026

Argo Biopharma’s investigational siRNA therapy BW-20805 showed sustained reduction in hereditary angioedema attack rates and plasma prekallikrein levels, with favorable safety, in Phase II interim data selected for AAAAI 2026.

AAAAI 2026 | 27/02/2026 | By News Bureau

Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026

Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.

AAAAI 2026 | 12/02/2026 | By News Bureau | 101

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members